Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
Condition: Influenza Disease; Flu
MeSH terms: Influenza, Human
Intervention: Influenza Virus Vaccine
Phase: Phase 2
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Enrollment: 613.0
Sex: All
Minimum age: 18 Years
Maximum age: 49 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: influenza; flu

Summary:

      The purpose of this study is to evaluate the safety and immunogenicity of cell
      culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin
      vaccine administered to healthy adults ages 18 < 50 years.
    

Eligibility criteria:

        Inclusion Criteria:

        18 to <50 years of age;

          1. able to comprehend and follow all required study procedures;

          2. able and willing to provide written informed consent prior to study entry;

          3. available for all the visits scheduled in the study;

          4. in general good health as determined by:

               1. subject-reported medical history,

               2. physical examination by a qualified study nurse, a physician's assistant, or a
                  physician,

               3. clinical judgment of the investigator; among all female volunteers, evidence of a
                  negative pregnancy test conducted on the same day as and prior to study
                  vaccination, and agreement to practice adequate contraception for at least 6
                  weeks after vaccination as further described in the protocol.

        Exclusion Criteria:

          1. received influenza vaccine within the past 6 months;

          2. laboratory-confirmed influenza disease in the past 6 months;

          3. any acute respiratory disease or infection requiring systemic antibiotic or antiviral
             therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or
             fever ≥38°C (100.4°F) within the past 3 days;

          4. receipt of another investigational agent within 90 days or before completion of the
             safety follow-up period in another study, whichever was longer, prior to enrollment,
             and unwilling to refuse participation in another investigational study through the end
             of the study;

          5. any history of or current serious disease, such as: d) cancer (except for benign or
             localized skin cancer), e) autoimmune disease (including rheumatoid arthritis), f)
             advanced arteriosclerotic disease or diabetes mellitus, g) chronic obstructive
             pulmonary disease (COPD), h) acute, chronic, or progressive hepatic disease, i) acute,
             chronic, or progressive renal disease, j) congestive heart failure, k) bleeding
             diathesis, l) an inherited genetic anomaly (known cytogenic disorders, e.g., Down's
             Syndrome), m) any other serious, acute, or chronic disease including progressive
             neurological disease or seizure disorder unrelated to fever;

          6. surgery or hospitalization planned during the study period;

          7. history of any anaphylaxis, serious vaccine reactions, vaccine-associated
             oculorespiratory syndrome, or allergy to eggs, egg products, mercury-containing
             compounds (such as sodium-ethyl-mercuro-thio-salicylate), or any other vaccine
             component or component of the potential packaging materials (latex);

          8. known or suspected disease of the immune system, or receiving immunosuppressive
             therapy, including use of: n) systemic corticosteroids, known to be associated with
             suppression of the hypothalamic-pituitary-adrenal (HPA) axis (i.e., systemic
             corticosteroids [15 mg/day of prednisone or its equivalent] or chronic use of inhaled
             high potency corticosteroids [budesonide 800 μg/day or fluticasone 750 μg/day]), both
             within the previous 60 days, o) receipt of immunostimulants within 60 days, p) receipt
             of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives
             within the 3 months prior to study entry or anticipated during the full length of the
             study;

          9. at high risk for developing an immunocompromising disease;

         10. history of (or current) drug or alcohol abuse that in the investigator's opinion would
             interfere with safety of the subject or the evaluation of study objectives;

         11. pregnant or breastfeeding;

         12. if female of childbearing potential, refusal to use a reliable contraceptive method,
             as described further in the protocol, during the first 6 weeks after vaccination;

         13. if female of childbearing potential and sexually active, has not used any of the
             following birth control methods for the specified time period prior to study entry:

               1. hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring),
                  barrier (e.g., condom with spermicide or diaphragm with spermicide), or
                  intrauterine device (e.g., IUD) for 2 months or more prior to study entry,

               2. monogamous relationship with vasectomized partner: partner has been vasectomized
                  for 6 months or more prior to the subject's study entry;

         14. obese (e.g., with a body mass index [BMI] ≥35, where BMI reflects obesity and not high
             muscle mass);

         15. any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives or might interfere with the safety of the study
             subject.